These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19473616)

  • 21. Subclinical Fabry's disease occurring in the context of IgA nephropathy.
    Kawamura O; Sakuraba H; Itoh K; Suzuki Y; Doi M; Kuwabara H; Oshima S; Abe S; Warabi H; Yoshizawa N
    Clin Nephrol; 1997 Feb; 47(2):71-5. PubMed ID: 9049452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy for Fabry's disease.
    Deegan P
    Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
    [No Abstract]   [Full Text] [Related]  

  • 24. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.
    Masugata H; Senda S; Goda F; Yamagami A; Okuyama H; Kohno T; Hosomi N; Yukiiri K; Noma T; Murao K; Kohno M; Itoh S
    Tohoku J Exp Med; 2009 Mar; 217(3):169-74. PubMed ID: 19282651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
    Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
    G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
    Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
    Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renal lesions in patients with Fabry's disease].
    Gubler MC
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S220-5. PubMed ID: 21211668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.
    Mehta A; Beck M; Elliott P; Giugliani R; Linhart A; Sunder-Plassmann G; Schiffmann R; Barbey F; Ries M; Clarke JT;
    Lancet; 2009 Dec; 374(9706):1986-96. PubMed ID: 19959221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry's disease without angiokeratomas showing unusual eccrine gland vacuolation.
    Idoate MA; Pardo-Mindan FJ; Gonzalez Alamillo C
    J Pathol; 1992 May; 167(1):65-8. PubMed ID: 1625060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First treatment for Fabry's disease.
    FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.
    Prinz C; Farr M; Hering D; Horstkotte D; Faber L
    Clin Res Cardiol; 2010 Jan; 99(1):53-5. PubMed ID: 19774328
    [No Abstract]   [Full Text] [Related]  

  • 34. Fabrazyme--recombinant protein treatment for Fabry's disease.
    Barngrover D
    J Biotechnol; 2002 May; 95(3):280-2. PubMed ID: 12080957
    [No Abstract]   [Full Text] [Related]  

  • 35. Enzyme therapy for Fabry's disease: registered for success?
    Knebelmann B; Kurschat C; Thadhani R
    Lancet; 2009 Dec; 374(9706):1950-1. PubMed ID: 19959220
    [No Abstract]   [Full Text] [Related]  

  • 36. Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.
    Odani K; Okumi M; Honda K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():57-9. PubMed ID: 26971403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac involvement in Fabry's disease.
    Nicholls K
    Heart Lung Circ; 2005; 14 Suppl 2():S18-20. PubMed ID: 16352280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.
    Sakuraba H; Murata-Ohsawa M; Kawashima I; Tajima Y; Kotani M; Ohshima T; Chiba Y; Takashiba M; Jigami Y; Fukushige T; Kanzaki T; Itoh K
    J Hum Genet; 2006; 51(3):180-188. PubMed ID: 16372133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PR interval and the response to enzyme-replacement therapy for Fabry's disease.
    Waldek S
    N Engl J Med; 2003 Mar; 348(12):1186-7. PubMed ID: 12646684
    [No Abstract]   [Full Text] [Related]  

  • 40. Enzyme replacement therapy in patients with Fabry's disease.
    Tsuboi K
    J Int Med Res; 2007; 35(4):574-81. PubMed ID: 17697536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.